Pharsight

Accrufer generic

Accrufer is an iron deficiency treatment drug owned by Shield Tx. The active ingredient of Accrufer is ferric maltol. This drug was first authorized for market use on 25 July, 2019.

When will Accrufer generic be available?

Accrufer has a total of 3 drug patents. A generic version of the drug could be released after the final patent expires on 23 October, 2035. It's important to note that drug patent challenges against Accrufer can begin from 26 July, 2023, further influencing the availability date of Accrufer generics.

Accrufer uses

Accrufer is used to treat iron deficiency. Its effectiveness is attributed to its active ingredient, ferric maltol, which helps in increasing the iron levels in the body. Accrufer is available in capsule form for oral administration.

Accrufer patent expiration

Accrufer holds 3 patents with the last one expiring on 23rd October, 2035. These patents protect the unique composition and dosage regimens of the drug, impacting the release date of Accrufer generic. Below are the details of the patents:

EPO Oppostions filed on Accrufer

Accrufer dosage

Want to ask something?